3rd Quarter - Report
TODD STRATEGY GROUP for NOVARTIS, INC.
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Supply Chain. 340B Issues. Biologics Price Competition and Innovation Act. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. Advanced Research Projects Agency for Health funding issues. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL | Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg |
| JEFF LUCAS | Health Policy Advisor, Senator Bill Cassidy; Legislative Assistant/Sr. Legislative Assistant/Legislative Correspondent, Representative Larry Bucshon |
| DANIEL M TODD | Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid |
| NICHOLAS UEHLECKE | Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee |
Medicare/Medicaid MMM
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL | — |
| JEFF LUCAS | — |
| DANIEL M TODD | — |
| NICHOLAS UEHLECKE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.